Compare · IMNM vs LLY
IMNM vs LLY
Side-by-side comparison of Immunome Inc. (IMNM) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMNM and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.11T, about 439.3x IMNM ($2.53B).
- IMNM has been more active in the news (7 items in the past 4 weeks vs 5 for LLY).
- LLY has more recent analyst coverage (25 ratings vs 13 for IMNM).
- Company
- Immunome Inc.
- Eli Lilly and Company
- Price
- -
- -
- Market cap
- $2.53B
- $1.11T
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 7
- 5
- Recent ratings
- 13
- 25
Immunome Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest IMNM
- CHIEF BUSINESS OFFICER Horn Kinney exercised 1,092 shares at a strike of $12.92 and sold $27,300 worth of shares (1,092 units at $25.00) as part of a pre-agreed trading plan (SEC Form 4)
- Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
- Director Barchas Isaac sold $2,412,522 worth of shares (100,000 units at $24.13) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Lechleider Robert exercised 55,000 shares at a strike of $8.73 and sold $1,244,331 worth of shares (55,000 units at $22.62) as part of a pre-agreed trading plan (SEC Form 4)
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Barchas Isaac sold $4,393,024 worth of shares (201,050 units at $21.85) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Lechleider Robert exercised 55,000 shares at a strike of $8.73 and sold $1,091,662 worth of shares (55,000 units at $19.85) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Rosett Max sold $1,093,800 worth of shares (60,000 units at $18.23) as part of a pre-agreed trading plan and exercised 60,000 shares at a strike of $1.05 (SEC Form 4)
- SEC Form 4 filed by Director Swain Sandra M
- SEC Form 4 filed by Director Wagenheim Philip
Latest LLY
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
- Three Biotechs Deliver Catalysts to Watch
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
- SEC Form 11-K filed by Eli Lilly and Company
- Lilly declares third-quarter 2026 dividend